- $467.24m
- $252.03m
- $236.84m
- 76
- 31
- 42
- 48
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 36.2 | 52.5 | 111 | 168 | 237 |
Cost of Revenue | |||||
Gross Profit | -1.05 | -4.3 | -10.1 | 1.35 | 49.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 66.1 | 88.3 | 182 | 272 | 280 |
Operating Profit | -29.8 | -35.7 | -71.7 | -104 | -43.2 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30.3 | -37 | -71.8 | -102 | -34.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -30.3 | -37.1 | -72 | -96.3 | -34.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -30.3 | -37.1 | -72 | -96.3 | -34.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.5 | -37.1 | -72 | -96.3 | -34.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.174 | -0.192 | -0.963 | -0.481 | -0.168 |
Dividends per Share |